Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pre-Eclampsia - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Pre-Eclampsia - Pipeline Review, H2 2016', provides an overview of the Pre-Eclampsia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia - The report reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects - The report assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pre-Eclampsia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pre-Eclampsia Overview 6 Therapeutics Development 7 Pipeline Products for Pre-Eclampsia - Overview 7 Pipeline Products for Pre-Eclampsia - Comparative Analysis 8 Pre-Eclampsia - Therapeutics under Development by Companies 9 Pre-Eclampsia - Therapeutics under Investigation by Universities/Institutes 10 Pre-Eclampsia - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Pre-Eclampsia - Products under Development by Companies 13 Pre-Eclampsia - Products under Investigation by Universities/Institutes 14 Pre-Eclampsia - Companies Involved in Therapeutics Development 15 A1M Pharma AB 15 Alnylam Pharmaceuticals, Inc. 16 Glenveigh Medical, LLC 17 LFB S.A. 18 Pluristem Therapeutics Inc. 19 VG Life Sciences, Inc. 20 Pre-Eclampsia - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 A1M-001 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 ALN-AGT - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 antithrombin (recombinant) - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 digoxin immune fab - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 PLX-PAD - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 RMC-035 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Small Molecules to Agonize Apelin Receptor for Pre-Eclampsia - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 VG-1177 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Pre-Eclampsia - Dormant Projects 51 Pre-Eclampsia - Product Development Milestones 52 Featured News & Press Releases 52 Mar 22, 2016: A1M Pharma finalizes drug candidate for treating pre-eclampsia and files for substance patent 52 Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Pre-eclampsia 52 Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Pre-eclampsia and Indicates Their Superiority Over Other Cells 53 Dec 31, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem's PLX-PAD Cells for Treatment of Severe Pre-eclampsia 54 Sep 24, 2015: New clinical trial at SLU treats pre-eclampsia in second-trimester pregnancies 54 Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Pre-eclampsia 55 Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting 57 Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Pre-eclampsia (PRESERVE-1) 57 Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma's Treatment for Pre-eclampsia 58 Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Pre-eclampsia 58 Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Pre-eclampsia 59 Feb 20, 2014: Pluristem Submits FDA Orphan Drug Application for Pre-eclampsia 60 Nov 04, 2013: Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model 60 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Number of Products under Development for Pre-Eclampsia, H2 2016 7 Number of Products under Development for Pre-Eclampsia - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Pre-Eclampsia - Pipeline by A1M Pharma AB, H2 2016 15 Pre-Eclampsia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 16 Pre-Eclampsia - Pipeline by Glenveigh Medical, LLC, H2 2016 17 Pre-Eclampsia - Pipeline by LFB S.A., H2 2016 18 Pre-Eclampsia - Pipeline by Pluristem Therapeutics Inc., H2 2016 19 Pre-Eclampsia - Pipeline by VG Life Sciences, Inc., H2 2016 20 Assessment by Monotherapy Products, H2 2016 21 Number of Products by Stage and Target, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Pre-Eclampsia - Dormant Projects, H2 2016 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
